Glenmark’s innovation subsidiary, Ichnos, highlights encouraging early data for lead bispecific antibody assets and hopes to accelerate these via licensing and partnership deals.The US-based arm also points to the tough biopharma financing market where investors are no longer satisfied with just the “preclinical story”.

Leaders from three companies that have managed to achieve successful turnarounds offered some advice and encouragement to biotechs weathering the current financial downturn at the recent Jefferies Healthcare conference in London.

California biotech also notes prior licensing deal with Gilead for mitochondrial candidate. Twentyeight-Seven acquires RNA-splicing cancer candidate from Basilea.

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker